← Back to Clinical Trials
Recruiting Phase 2, Phase 3 NCT07229651

Metformin in Parkinson Disease

Trial Parameters

Condition Parkinson Disease
Sponsor Tanta University
Study Type INTERVENTIONAL
Phase Phase 2, Phase 3
Enrollment 60
Sex ALL
Min Age 50 Years
Max Age 70 Years
Start Date 2025-11-10
Completion 2026-11-20
Interventions
Levodopa CarbidopaMetformin

Brief Summary

The clinical manifestations of Parkinson's disease (PD), a chronic neurodegenerative condition, include resting tremor, hypokinesia, bradykinesia, stiffness and postural instability. These motor symptoms are caused by a selective loss and degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc) region, which leads to a dopamine (DA) insufficiency in the striatum

Eligibility Criteria

Inclusion Criteria: Eligible participants were men and women aged 50 years or older with a confirmed diagnosis of PD Patients receiving levodopa/carbidopa therapy. Exclusion Criteria: Secondary causes of parkinsonism Patients taking anti-inflammatory drugs Atypical parkinsonian syndromes Prior stereotaxic surgery for Parkinson's disease Pregnancy and lactation Cardiovascular disease patients Patients with coagulation disorders Suffering from active malignancy Addiction to alcohol and / or drugs Known allergy to the studied medications

Related Trials